Cargando…

Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?

BACKGROUND: The implantation protocol for Carmustine Wafers (CWs) in high grade glioma (HGG) was developed to offer a bridge between surgical resection and adjuvant treatments, such as radio- and chemotherapy. In the last years, however, a widespread use of CWs has been limited due to uncertainties...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricciardi, Luca, Manini, Ivana, Cesselli, Daniela, Trungu, Sokol, Piazza, Amedeo, Mangraviti, Antonella, Miscusi, Massimo, Raco, Antonino, Ius, Tamara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259966/
https://www.ncbi.nlm.nih.gov/pubmed/35812101
http://dx.doi.org/10.3389/fneur.2022.884158
_version_ 1784741907294846976
author Ricciardi, Luca
Manini, Ivana
Cesselli, Daniela
Trungu, Sokol
Piazza, Amedeo
Mangraviti, Antonella
Miscusi, Massimo
Raco, Antonino
Ius, Tamara
author_facet Ricciardi, Luca
Manini, Ivana
Cesselli, Daniela
Trungu, Sokol
Piazza, Amedeo
Mangraviti, Antonella
Miscusi, Massimo
Raco, Antonino
Ius, Tamara
author_sort Ricciardi, Luca
collection PubMed
description BACKGROUND: The implantation protocol for Carmustine Wafers (CWs) in high grade glioma (HGG) was developed to offer a bridge between surgical resection and adjuvant treatments, such as radio- and chemotherapy. In the last years, however, a widespread use of CWs has been limited due to uncertainties regarding efficacy, in addition to increased risk of infection and elevated costs of treatment. OBJECTIVE: The aims of our study were to investigate the epidemiology of patients that underwent surgery for HGG with CW implantation, in addition to the assessment of related complications, long-term overall survival (OS), and associated prognostic factors. METHODS: Three different medical databases were screened for conducting a systematic review of the literature, according to the PRISMA statement guidelines, evaluating the role of BCNU wafer implantation in patients with newly diagnosed HGG. The search query was based on a combination of medical subject headings (MeSH): “high grade glioma” [MeSH] AND “Carmustine” [MeSH] and free text terms: “surgery” OR “BCNU wafer” OR “Gliadel” OR “systemic treatment options” OR “overall survival.” RESULTS: The analysis of the meta-data demonstrated that there was a significant advantage in using CWs in newly diagnosed GBM in terms of OS, and a very low heterogeneity among the included studies [mean difference 2.64 (95% CI 0.85, 4.44); p = 0.004; I2149 = 0%]. Conversely, no significant difference between the two treatment groups in terms of PFS wad detected (p = 0.55). The analysis of complications showed a relatively higher rate in Carmustine implanted patients, although this difference was not significant (p = 0.53). CONCLUSIONS: This meta-analysis seems to suggest that CWs implantation plays a significant role in improving the OS, when used in patients with newly diagnosed HGG. To minimize the risk of side effects, however, a carful patient selection based mainly on patient age and tumor volume should be desirable.
format Online
Article
Text
id pubmed-9259966
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92599662022-07-08 Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option? Ricciardi, Luca Manini, Ivana Cesselli, Daniela Trungu, Sokol Piazza, Amedeo Mangraviti, Antonella Miscusi, Massimo Raco, Antonino Ius, Tamara Front Neurol Neurology BACKGROUND: The implantation protocol for Carmustine Wafers (CWs) in high grade glioma (HGG) was developed to offer a bridge between surgical resection and adjuvant treatments, such as radio- and chemotherapy. In the last years, however, a widespread use of CWs has been limited due to uncertainties regarding efficacy, in addition to increased risk of infection and elevated costs of treatment. OBJECTIVE: The aims of our study were to investigate the epidemiology of patients that underwent surgery for HGG with CW implantation, in addition to the assessment of related complications, long-term overall survival (OS), and associated prognostic factors. METHODS: Three different medical databases were screened for conducting a systematic review of the literature, according to the PRISMA statement guidelines, evaluating the role of BCNU wafer implantation in patients with newly diagnosed HGG. The search query was based on a combination of medical subject headings (MeSH): “high grade glioma” [MeSH] AND “Carmustine” [MeSH] and free text terms: “surgery” OR “BCNU wafer” OR “Gliadel” OR “systemic treatment options” OR “overall survival.” RESULTS: The analysis of the meta-data demonstrated that there was a significant advantage in using CWs in newly diagnosed GBM in terms of OS, and a very low heterogeneity among the included studies [mean difference 2.64 (95% CI 0.85, 4.44); p = 0.004; I2149 = 0%]. Conversely, no significant difference between the two treatment groups in terms of PFS wad detected (p = 0.55). The analysis of complications showed a relatively higher rate in Carmustine implanted patients, although this difference was not significant (p = 0.53). CONCLUSIONS: This meta-analysis seems to suggest that CWs implantation plays a significant role in improving the OS, when used in patients with newly diagnosed HGG. To minimize the risk of side effects, however, a carful patient selection based mainly on patient age and tumor volume should be desirable. Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9259966/ /pubmed/35812101 http://dx.doi.org/10.3389/fneur.2022.884158 Text en Copyright © 2022 Ricciardi, Manini, Cesselli, Trungu, Piazza, Mangraviti, Miscusi, Raco and Ius. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Ricciardi, Luca
Manini, Ivana
Cesselli, Daniela
Trungu, Sokol
Piazza, Amedeo
Mangraviti, Antonella
Miscusi, Massimo
Raco, Antonino
Ius, Tamara
Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
title Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
title_full Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
title_fullStr Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
title_full_unstemmed Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
title_short Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
title_sort carmustine wafers implantation in patients with newly diagnosed high grade glioma: is it still an option?
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259966/
https://www.ncbi.nlm.nih.gov/pubmed/35812101
http://dx.doi.org/10.3389/fneur.2022.884158
work_keys_str_mv AT ricciardiluca carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption
AT maniniivana carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption
AT cessellidaniela carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption
AT trungusokol carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption
AT piazzaamedeo carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption
AT mangravitiantonella carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption
AT miscusimassimo carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption
AT racoantonino carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption
AT iustamara carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption